Metformina + Vildagliptina Mylan

Metformin Hydrochloride and Vildagliptin, the active ingredient in Metformina + Vildagliptina Mylan, is a Biguanide / DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults, helping to control blood glucose levels when used with diet and exercise.

GNH USA supplies Metformina + Vildagliptina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All batches are manufactured under EU GMP guidelines and undergo rigorous quality testing before release.

Metformina + Vildagliptina is indicated for managing hyperglycemia in the type 2 diabetes mellitus pathway.

- Type 2 diabetes mellitus: improves overall glycemic control when combined with diet and exercise. - Adjunct therapy: enhances insulin secretion and reduces hepatic glucose output in patients inadequately controlled on monotherapy. - Combination therapy: provides a dual mechanism to lower HbA1c levels in adults with persistent hyperglycemia.

Metformina + Vildagliptina may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea, often transient during treatment initiation. - Headache: mild to moderate intensity, usually resolves without intervention. - Hypoglycemia: especially when used with insulin or sulfonylureas, requiring glucose monitoring.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal metabolic complication, presenting with malaise, myalgia, and rapid breathing. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, requiring immediate discontinuation. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain, vomiting, and elevated enzymes.

When prescribing Metformina + Vildagliptina, clinicians should consider several precautionary measures to ensure patient safety.

- Renal function: assess baseline creatinine clearance and monitor periodically. - Hepatic disease: use with caution in patients with liver impairment. - Risk of lactic acidosis: avoid in severe renal insufficiency or conditions predisposing to hypoxia. - Pregnancy and lactation: safety not established; prescribe only if potential benefit justifies risk. - Hypoglycemia monitoring: increase vigilance when combined with other glucose‑lowering agents. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metformina + Vildagliptina can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: may cause severe hypoglycemia. - Iodinated contrast agents: can precipitate renal impairment, increasing metformin accumulation risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise vildagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal function, requiring dose adjustment. - ACE inhibitors or ARBs: monitor renal parameters and potassium. - Beta‑blockers: can mask hypoglycemia symptoms, necessitating closer glucose monitoring.